SELLAS Life Sciences Reports Breakthrough Results for SLS009
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) has announced compelling data from the third cohort of its ongoing Phase 2 clinical trial for SLS009, a promising treatment for relapsed or refractory acute myeloid leukemia (r/r AML). The results demonstrate encouraging overall survival rates, marking a significant achievement for patients enduring this challenging condition.
Noteworthy Survival Statistics
The latest findings reveal a median overall survival (mOS) of 8.9 months in patients suffering from AML with myelodysplasia-related changes (AML-MRC), and an 8.8 months mOS for all patients resistant to venetoclax-based therapies. This vastly exceeds historical benchmarks that previously set overall survival at a mere 2.5 months, showcasing the potential of SLS009 to improve patient outcomes significantly.
Response Rates Exceed Expectations
In addition to survival rates, the clinical trial has recorded a remarkable overall response rate (ORR) of 67% among AML-MRC patients. This figure is well above the pre-established target ORR of 20%. For the entire cohort, the ORR stands at 46%, indicating that SLS009 is not only saving lives but also effectively responding to treatment across diverse patient segments.
Patient Involvement and Responses
The trial included 14 patients previously treated with venetoclax, with an average age of 71. Notably, a significant portion of these patients had AML-MRC, a subtype that often poses greater challenges in treatment response. Among those with the myelomonocytic phenotype, a staggering 75% responded positively to the treatment.
Genetic Considerations in Treatment
The results also highlight the importance of genetic factors in therapeutic response. Patients with specific mutations, such as ASXL1 and RUNX1, showed high response rates, further suggesting that SLS009 could serve tailored treatment options for high-risk patient groups traditionally facing poorer prognoses.
Continued Development and Future Prospects
SELLAS is committed to advancing the development of SLS009 and is currently expanding the trial to include further cohorts designed to evaluate its efficacy in broader patient populations. The ongoing Phase 2 trial aims to address unmet medical needs through rigorous testing, focusing on both safety and efficacy of the treatment. Responses to SLS009 thus far have been well tolerated by participants, with no new safety concerns raised in the prolonged clinical observation.
The Path Ahead for SLS009
The promising outcomes from this trial not only underscore SLS009’s potential as a standout treatment in the evolving landscape of AML therapies, but they also pave the way for future trials to establish robust data to further its use among high-risk groups. With valuable insights garnered from these trial phases, SELLAS is poised to contribute profoundly to cancer therapeutics.
About SELLAS Life Sciences Group, Inc.
SELLAS is a biopharmaceutical company engaged in developing innovative therapies to combat a range of cancer types. Their lead candidate, GPS, targets the WT1 protein across various malignancies, while SLS009 is positioned as a novel CDK9 inhibitor that promises better efficacy and safety profiles compared to existing treatments. The company’s commitment to tackling hematologic malignancies highlights its role in transforming cancer care.
Frequently Asked Questions
What is SLS009?
SLS009, or tambiciclib, is a selective CDK9 inhibitor being evaluated for treating relapsed/refractory acute myeloid leukemia.
What were the key findings from the trial?
The trial showed a median overall survival of 8.9 months in AML-MRC patients and a 67% overall response rate among this group.
Who conducted the trial?
The trial was conducted by SELLAS Life Sciences Group, Inc., a company focused on developing therapies for cancer patients.
What does the response rate indicate?
The 67% response rate signifies that the treatment is effectively working for a significant portion of patients previously resistant to other therapies.
What are the next steps for SELLAS?
SELLAS plans to expand the trial to further cohorts to validate SLS009's efficacy and safety for additional populations within the AML patient community.
